Abstract
The overall medical oncological strategies available up to now in the treatment of human neoplasms are performed to counteract cancer dissemination through blocking the proliferation of single cancer cells by several mechanisms. These mechanisms include suppression of angiogenesis, which is essential for cancer growth, inhibition of tumor growth factor receptor expression and protein kinase activation, DNA damage, and induction of apoptosis. However, it has to be noted that tumor growth does not depend only on the genetic characteristics of cancer cells but also on host immune status. Therefore, an evident limitation of anticancer medical therapies such as recent target therapies is neglecting patients’ immune status. Moreover, due to the exclusion of some other fundamental mechanisms, other limitations within the same dynamics of cancer cell proliferation exist such as alterations of the intercellular junctions and the following modifications of the intercellular matrix, which are essential for neoangiogenetic process induction. Several recent clinical studies have demonstrated that at the beginning of the neoplastic disease, there is an immunosuppressive status depending on an altered psychoneuroendocrine regulation of the antitumor immunity, which would be responsible for the evolution of the single transformed cell into a clinically evident tumor mass and substantially consisting of hyperactivation of the brain opioid system associated with a progressive decline in brain cannabinoid system and pineal gland functions. Finally, it has been demonstrated that the great number of cancer-related endocrine, neuroendocrine, and immune alterations involving both cytokine secretion and immune cell differentiation may play a role in promoting cancer dissemination. In more detail, IL-2 and IL-12 deficiencies in association with a progressive decline in pineal endocrine function would represent the main immune and endocrine anomalies, respectively. On this basis, cancer PNEI therapy simply consists of the correction of the main cancer-related immune and neuroendocrine alterations through substitute replacement therapy. At present, promising results in terms of enhanced survival time and improved quality of life have been described by a psychoneuroimmune regimen consisting of subcutaneous low-dose IL-2 and IL-12 in association with antitumor pineal hormones.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Riesco A. Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer. 1970;25:135–40.
Antoni M, Lutgendorf S, Cole S, et al. The influence of behavioural factors on tumor biology: pathways and mechanisms. Nat Rev Cancer. 2006;6:240–8.
Jankovic BD. Neuroimmunomodulation. From phenomenology to molecular evidence. Ann N Y Acad Sci. 1994;741:3–38.
Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186–95.
Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol. 2006;6:295–307.
Lissoni P, Fumagalli L, Rovelli F, Brivio F, Di Felice G, Majorca F. In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients. Br J Cancer. 1998;77:1957–60.
Schwartz RH. Natural regulatory T cells and self-tolerance. Nat Immunol. 2005;6:326–30.
Cesana GC, De Raffaele G, Cohen S, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24:1169–77.
Plotnikoff NP, Miller GC. Enkephalins as immunomodulators. Int J Immunopharmacol. 1983;5:437–42.
Wybran J, Appelboom T, Famaey JP, Govaerts A. Suggestive evidence for morphine and methionine-enkephalin receptors on normal T lymphocytes. J Immunol. 1979;123:1068–72.
Grotenhermen F. Pharmacology of cannabinoids. Neuroendocrinol Lett. 2004;25:14–22.
Sze SF, Ng TB, Liu WK. Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res. 1993;14:27–33.
Kim R, Emi M, Tanabe K, Uchida Y, Toge T. The role of Fas ligand and transforming growth factor-beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential target for cancer therapy. Cancer. 2004;100:2281–91.
Mazzoccoli G, Carughi S, De Cata A, et al. Neuroendocrine alterations in lung cancer patients. Neuroendocrinol Lett. 2003;24:77–82.
Lissoni P, Cangemi P, Pirato D, et al. A review on cancer-psychospiritual status interactions. Neuroendocrinol Lett. 2001;22:175–80.
Wittington R, Faulds D. Interleukin-2. Drugs. 1993;46:4466–83.
Lissoni P, Mandalà M, Mandelli A, Fumagalli L. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 plus the pineal oncostatic hormones melatonin and 5-methoxytryptamine in untreatable advanced solid neoplasm patients with poor clinical status. Int J Immunother. 1999;XV:35–8.
Lissoni P, Barni S, Tancini G, et al. A randomized study with subcutaneous low-dose interleuikin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer. 1994;69:196–9.
Lissoni P, Pittalis S, Rovelli F, et al. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer. J Biol Regul Homeost Agents. 1995;9:63–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lissoni, P., Messina, G., Rovelli, F. (2015). Psychoneuroendocrinoimmunotherapy of Cancer. In: Rezaei, N. (eds) Cancer Immunology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44946-2_26
Download citation
DOI: https://doi.org/10.1007/978-3-662-44946-2_26
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-44945-5
Online ISBN: 978-3-662-44946-2
eBook Packages: MedicineMedicine (R0)